After a government report confirmed major ethical violations in trials of Human Papilloma Virus (HPV) vaccines on Indian schoolgirls, senior doctors are calling for transparency in clinical trials conducted under private-public partnerships. The report is yet to be placed in the public domain, but its contents were revealed early May by senior doctors who assisted in its preparation, sparking outrage among public health advocates and women’s rights groups. HPV is an umbrella...
More »SEARCH RESULT
Details of patented drugs to be made public by CH Unnikrishnan
To increase transparency, India’s patent regulator will soon make public details about patented drugs which include whether domestic demand for these medicines is met at a reasonable price. Patent holders in the country are required to submit once every year the so-called working details which include the quantity and value of a product that is sold, manufacturing base, quantity of production or imports, and a statement on whether public requirement has...
More »Drug regulator cover on vaccine study aim by GS Mudur
India’s drug regulator has refused to disclose key information about a controversial government study that provided Indian girls a vaccine designed to protect them from cervical cancer, amplifying suspicions about the study’s objectives. The Drug Controller General of India (DCGI) has refused to release for public scrutiny the study’s protocols, which are expected to contain information about its purpose and methodology, a set of health activists said yesterday. The Union government had...
More »RTI Act not applicable to HPV vaccine project by Aarti Dhar
‘Trade secret of third party' can't be disclosed: Drugs-Controller Application seeks information on the basis of approval for import and marketing of vaccines It seeks to know protocols for permission to an NGO and ICMR to conduct ‘demonstration project' Information on the demonstration project and licensing of two vaccines to prevent cervical cancer has been exempted from public disclosure under Section 8 of the Right to Information Act, 2005. This is the reply received...
More »Three firms rank highest on access to poor by Donald G. Mcneil Jr
GlaxoSmithKline, Merck and Novartis have taken the top three spots again on the Access to Medicine Index, which ranks pharmaceutical companies on how readily they make their products available to the world's poor. It was the second time the rankings, which were created in 2008, have been issued. This time, 95 per cent of the brand-name companies approached by the Dutch foundation that started the index agreed to provide information;...
More »